1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ESMO 24: Replimune’s Cancer Vaccine Succeeds In PD-1 Failures

 
• By Elizabeth Cairns

New data suggest that RP1 could become the therapy of choice in melanoma patients who do not respond to checkpoint inhibitors.    

Medical concept Vaccination vaccine vial dose flu shot drug needle syringe,Lab test research science hypodermic injection treatment disease care hospital prevention immunization illness disease baby.

Checkpoint inhibitors have revolutionized cancer treatment, but they aren’t perfect, and there is a niche for therapies to treat those whose disease progresses despite receiving these therapies. Replimune Group Inc. believes its cancer vaccine RP1 (vusolimogene oderparepvec) could become the go-to option for melanoma patients in this situation following an impressive update from the IGNYTE trial.

Key Takeaways
  • New data from the IGNYTE trial of Replimune’s oncolytic vaccine RP1 show impressive rates of response and survival in a post-PD-1 population.

The new data cut was presented at the European Society for Medical Oncology meeting in Barcelona, Spain, on 15 September....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Vertex’s Pain Drug Failure Adds To Investor Doubts

 
• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death

 
• By Alaric DeArment

The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.

More from R&D

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging

 
• By Aakash Babu

The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.